GlassScriptPhysician profile
Caroline P Conley
NPI 1538514617
$1,324.30
in general payments reported to CMS, 2019-2025
19 companies · $579 in 2025
The $579 reported for 2025 was more than what 76% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $158 · 2023: $292 · 2024: $297 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $409.48 | 2023-2025 | |
| Qol Medical, LLC | $160.18 | 2023-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $151.93 | 2022-2025 | Dupixent |
| Inari Medical, INC. | $125.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.55 | 2024-2025 | Eohilia, Gattex |
| Janssen Biotech, INC. | $72.13 | 2023-2025 | Stelara, Remicade, Simponi Aria |
| Nestle Healthcare Nutrition INC. | $47.44 | 2023 | |
| Albireo Pharma, INC. | $37.75 | 2022-2023 | Bylvay |
| Organon LLC | $33.18 | 2023-2024 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $28.76 | 2025 | Iqirvo |
| Abbvie INC. | $26.16 | 2023 | Creon, Linzess |
| Acadia Pharmaceuticals INC | $24.42 | 2025 | Daybue |
| Novo Nordisk INC | $21.28 | 2025 | Wegovy |
| Mirum Pharmaceuticals, INC. | $21.20 | 2023 | Livmarli |
| Alcresta Therapeutics, INC. | $20.65 | 2024 | Relizorb |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $19.74 | 2025 | Vegzelma |
| Orphalan INC | $17.42 | 2025 | Cuvrior |
| Coloplast Corp | $14.39 | 2025 | |
| Endogastric Solutions, INC | $14.38 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Conley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.